Stryker Corporation $SYK Shares Purchased by Bright Financial Advisors Inc.

Key Points

• Bright Financial Advisors Inc. increased its holdings in Stryker Corporation by 15.3%, now owning 22,345 shares valued at $8,840,000, making it Stryker's sixth largest stakeholder.
• Insider Ronda E. Stryker sold 200,000 shares valued at approximately $75.29 million, while Viju Menon sold 500 shares for around $195,305, reflecting a decrease in their ownership percentages.
• Recent analyst upgrades have improved Stryker's consensus rating to a "Moderate Buy" with a price target of $430.33, indicating positive expectations for the company's stock.

Bright Financial Advisors Inc. grew its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 15.3% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 22,345 shares of the medical technology company's stock after purchasing an additional 2,963 shares during the quarter. Stryker comprises about 4.9% of Bright Financial Advisors Inc.'s investment portfolio, making the stock its 6th largest position. Bright Financial Advisors Inc.'s holdings in Stryker were worth $8,840,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Brighton Jones LLC grew its holdings in Stryker by 15.4% during the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after acquiring an additional 609 shares during the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $67,000. Wood Tarver Financial Group LLC bought a new position in Stryker in the 4th quarter worth approximately $71,000. Centaurus Financial Inc. lifted its holdings in Stryker by 16.8% during the 4th quarter. Centaurus Financial Inc. now owns 1,246 shares of the medical technology company's stock worth $449,000 after buying an additional 179 shares in the last quarter. Finally, 111 Capital bought a new position in Stryker in the 4th quarter valued at $415,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Viju Menon sold 500 shares of the company's stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Wall Street Zen upgraded Stryker from a "hold" rating to a "buy" rating in a research report on Friday, July 18th. Rothschild Redb raised Stryker to a "hold" rating in a report on Thursday, September 18th. Needham & Company LLC raised their target price on shares of Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research note on Friday, August 1st. BTIG Research reiterated a "buy" rating on shares of Stryker in a research report on Monday, July 14th. Finally, Truist Financial set a $415.00 price objective on shares of Stryker and gave the company a "hold" rating in a report on Monday, August 4th. Fourteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, Stryker presently has a consensus rating of "Moderate Buy" and an average price target of $430.33.

Stryker Trading Down 0.7%

SYK opened at $368.64 on Friday. The firm's fifty day moving average is $386.11 and its two-hundred day moving average is $378.95. The firm has a market cap of $140.93 billion, a PE ratio of 48.83, a price-to-earnings-growth ratio of 2.68 and a beta of 0.93. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts' consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The firm's quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker's dividend payout ratio (DPR) is 44.50%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.